FDA Approves Mesenchymal Stromal Cell Therapy for Refractory Acute GVHD in Kids

(MedPage Today) -- Reaching the end of a long road to approval, the first mesenchymal stromal cell (MSC) therapy for steroid-refractory acute graft-versus-host disease (GVHD) finally reached the FDA green light.
The approval of remestemcel-L ...